Lorbrena (lorlatinib) - Pfizer
Rapid Lorlatinib Response in Lung Adenocarcinoma With a Novel Y Chromosome Intergenic ALK Fusion: A Case Report. (PubMed, Clin Lung Cancer) - Sep 29, 2026 - "CLINICAL PRACTICE POINTS." 
Journal • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
http://www.ncbi.nlm.nih.gov/pubmed/42804986
 
Jin-Ming Chen; Jing-Ru Luo; Shu Lin; Wen-Jun Tang; Yi-Fan Kang; Yue-Can Zeng
 
Sep 29, 2026
 
Prev Next